Aurobindo Pharma Limited

NSEI:AUROPHARMA Voorraadrapport

Marktkapitalisatie: ₹717.5b

Aurobindo Pharma Dividenden en inkoop

Dividend criteriumcontroles 2/6

Aurobindo Pharma is een dividendbetalend bedrijf met een huidig rendement van 0.24% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

0.2%

Dividendrendement

1.3%

Terugkoop Rendement

Totaal aandeelhoudersrendement1.5%
Toekomstig dividendrendement0.4%
Dividendgroei4.8%
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeel₹3.000
Uitbetalingsratio2%

Recente updates van dividend en inkoop

Recent updates

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: De dividendbetalingen van AUROPHARMA zijn de afgelopen 10 jaar volatiel geweest.

Groeiend dividend: De dividendbetalingen van AUROPHARMA zijn de afgelopen 10 jaar gestegen.


Dividendrendement versus markt

Aurobindo Pharma Dividendrendement versus markt
Hoe verhoudt AUROPHARMA dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (AUROPHARMA)0.2%
Markt onderkant 25% (IN)0.2%
Markt Top 25% (IN)1.2%
Gemiddelde industrie (Pharmaceuticals)0.7%
Analist prognose (AUROPHARMA) (tot 3 jaar)0.4%

Opmerkelijk dividend: Het dividend van AUROPHARMA ( 0.24% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de Indian markt ( 0.25% ).

Hoog dividend: Het dividend AUROPHARMA ( 0.24% ) is laag vergeleken met de top 25% van dividendbetalers in de Indian markt ( 1.15% ).


Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn lage payout ratio ( 2.4% ) worden de dividendbetalingen van AUROPHARMA grotendeels gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: AUROPHARMA keert dividend uit, maar het bedrijf heeft geen vrije kasstromen.


Ontdek bedrijven met een sterk dividend